Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04471727 · ClinicalTrials.gov registry record · Phase 1

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

A Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Carcinoma, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

Active
Registry status
Phase 1
Development phase
232
Enrollment target
11
Study locations

NCT04471727 is a Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Carcinoma that is active but no longer recruiting, run by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 232 participants, roughly in line with the 229-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target. The trial reports 11 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04471727, a Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Carcinoma, is active but no longer recruiting, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
232 participants
Enrollment target
11
Study locations

Study Summary

This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants with advanced cancers associated with expression of Delta-like Canonical Notch Ligand 3 (DLL3).

Conditions Studied

Small-cell Lung Cancer Neuroendocrine Carcinoma

Interventions

  • BIOLOGICAL Atezolizumab
  • BIOLOGICAL Gocatamig
  • BIOLOGICAL Ifinatamab Deruxtecan (I-DXd)

Study Locations (11)

California

  • Cedar-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute - Los Angeles
  • University of California San Francisco - San Francisco

New York

  • Roswell Park Comprehensive Cancer Center - Buffalo
  • Memorial Sloan Kettering Cancer Center - New York

Colorado

  • University of Colorado - Aurora

Massachusetts

  • Dana Farber Cancer Institute - Boston

Michigan

  • Karmanos Cancer Center - Detroit

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

Oregon

  • Providence - Portland

Tennessee

  • Tennessee Oncology - Nashville

Trial Details

FieldValue
Enrollment Target 232 participants
Start Date 2020-12-14
Est. Completion 2028-01-28
Phase Phase 1

Sponsor

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04471727

The ClinicalTrials.gov registry entry for NCT04471727 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 229-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target. The listed sponsor is Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.

NCT04471727 reports 11 study locations spanning 9 distinct geographic areas - top geographies include California, New York, Colorado.

Frequently Asked Questions

What is clinical trial NCT04471727 about?

NCT04471727 is a clinical study titled "A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)". This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants with advanced cancers associated with expression of Delta-like Canonical N...

What is the current status of trial NCT04471727?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 232 participants. The study started on 2020-12-14. Estimated completion is 2028-01-28.

What conditions does trial NCT04471727 study?

This clinical trial studies the following conditions: Small-cell Lung Cancer, Neuroendocrine Carcinoma.

What interventions are being tested in trial NCT04471727?

The interventions under investigation include: Atezolizumab (BIOLOGICAL), Gocatamig (BIOLOGICAL), Ifinatamab Deruxtecan (I-DXd) (BIOLOGICAL).

Who is sponsoring clinical trial NCT04471727?

This trial is sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04471727 being conducted?

This trial has 11 study locations across California, Colorado, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Small-cell Lung Cancer

All registered trials for this condition

Neuroendocrine Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.